Natixis Investment Managers International Biogen Inc. Transaction History

Natixis Investment Managers International

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$187.54 - $223.02 $2.03 Million - $2.41 Million	10,826 New	10,826 $2.21 Million
Q4 2018 Feb 14, 2019	SELL	$278.5 - $352.75 $964,445 - $1.22 Million	-3,463 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$293.51 - $383.83 $515,110 - $673,621	-1,755 Reduced 33.63%	3,463 $1.22 Million
Q2 2018 Aug 14, 2018	BUY	$257.52 - $306.91 $671,612 - $800,421	2,608 Added 99.92%	5,218 $1.51 Million
Q1 2018 May 15, 2018	BUY	$260.13 - $367.91 $678,939 - $960,245	2,610 New	2,610 $714,000

993

131M

1.12M

1.43M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $20.5B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Natixis Investment Managers International, based on Form 13F filings with the SEC.

Stay updated on Natixis Investment Managers International with notifications on news.